Granzyme B - Global Atherosclerosis Clinical Trials Rise Due to Higher Disease Incidences, Pipeline, H1 Review Till 2017

Granzyme B (C11 or CTLA 1 or Cathepsin G Like 1 or Cytotoxic T Lymphocyte Proteinase 2 or Fragmentin 2 or Granzyme 2 or Human Lymphocyte Protein or SECT or T Cell Serine Protease 1-3E or GZMB or EC 3.4.21.79) pipeline Target constitutes close to 10 molecules. Out of which approximately 10 molecules are developed by Companies. The latest report Granzyme B - Pipeline Review, H1 2017, outlays comprehensive information on the Granzyme B (C11 or CTLA 1 or Cathepsin G Like 1 or Cytotoxic T Lymphocyte Proteinase 2 or Fragmentin 2 or Granzyme 2 or Human Lymphocyte Protein or SECT or T Cell Serine Protease 1-3E or GZMB or EC 3.4.21.79) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Request For Free Sample @ http://www.marketresearchhub.com/enquiry.php?type=S&repid=1177485

Granzyme B (C11 or CTLA 1 or Cathepsin G Like 1 or Cytotoxic T Lymphocyte Proteinase 2 or Fragmentin 2 or Granzyme 2 or Human Lymphocyte Protein or SECT or T Cell Serine Protease 1-3E or GZMB or EC 3.4.21.79) - Granzyme B is a serine protease secreted by granules of cytotoxic lymphocytes (CTLs), natural killer cells (NK cells) and cytotoxic T cells. Granzyme B is crucial for the rapid induction of target cell death by apoptosis, induced by interaction with cytotoxic T cells. It activates the intracellular cascade of caspases finally resulting in the killing of the target cells. The molecules developed by companies in Preclinical and Discovery stages are 8 and 2 respectively. Report covers products from therapy areas Dermatology, Immunology, Cardiovascular, Metabolic Disorders, Central Nervous System, Oncology and Toxicology which include indications Diabetic Foot Ulcers, Aortic Aneurysm, Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE), Hypertrophic Scars, Keloids, Skin Ulcers, Wounds, Abdominal Aortic Aneurysms, Alopecia, Dermal Ulcers, Multiple Myeloma (Kahler Disease), Multiple Sclerosis, Radiodermatitis, Rheumatoid Arthritis and Systemic Sclerosis (Scleroderma).

Furthermore, this report also reviews key players involved in Granzyme B (C11 or CTLA 1 or Cathepsin G Like 1 or Cytotoxic T Lymphocyte Proteinase 2 or Fragmentin 2 or Granzyme 2 or Human Lymphocyte Protein or SECT or T Cell Serine Protease 1-3E or GZMB or EC 3.4.21.79) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

- The report provides a snapshot of the global therapeutic landscape for Granzyme B (C11 or CTLA 1 or Cathepsin G Like 1 or Cytotoxic T Lymphocyte Proteinase 2 or Fragmentin 2 or Granzyme 2 or Human Lymphocyte Protein or SECT or T Cell Serine Protease 1-3E or GZMB or EC 3.4.21.79)
- The report reviews Granzyme B (C11 or CTLA 1 or Cathepsin G Like 1 or Cytotoxic T Lymphocyte Proteinase 2 or Fragmentin 2 or Granzyme 2 or Human Lymphocyte Protein or SECT or T Cell Serine Protease 1-3E or GZMB or EC 3.4.21.79) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Granzyme B (C11 or CTLA 1 or Cathepsin G Like 1 or Cytotoxic T Lymphocyte Proteinase 2 or Fragmentin 2 or Granzyme 2 or Human Lymphocyte Protein or SECT or T Cell Serine Protease 1-3E or GZMB or EC 3.4.21.79) targeted therapeutics and enlists all their major and minor projects

Browse Full Report With TOC @ http://www.marketresearchhub.com/report/granzyme-b-c11-or-ctla-1-or-cathepsin-g-like-1-or-cytotoxic-t-lymphocyte-proteinase-2-or-fragmentin-2-or-granzyme-2-or-human-lymphocyte-protein-or-sect-or-t-cell-serine-protease-1-3e-or-gzmb-or-ec-342179-pipeline-review-h1-2017-report.html

- The report assesses Granzyme B (C11 or CTLA 1 or Cathepsin G Like 1 or Cytotoxic T Lymphocyte Proteinase 2 or Fragmentin 2 or Granzyme 2 or Human Lymphocyte Protein or SECT or T Cell Serine Protease 1-3E or GZMB or EC 3.4.21.79) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Granzyme B (C11 or CTLA 1 or Cathepsin G Like 1 or Cytotoxic T Lymphocyte Proteinase 2 or Fragmentin 2 or Granzyme 2 or Human Lymphocyte Protein or SECT or T Cell Serine Protease 1-3E or GZMB or EC 3.4.21.79) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Granzyme B (C11 or CTLA 1 or Cathepsin G Like 1 or Cytotoxic T Lymphocyte Proteinase 2 or Fragmentin 2 or Granzyme 2 or Human Lymphocyte Protein or SECT or T Cell Serine Protease 1-3E or GZMB or EC 3.4.21.79)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Granzyme B (C11 or CTLA 1 or Cathepsin G Like 1 or Cytotoxic T Lymphocyte Proteinase 2 or Fragmentin 2 or Granzyme 2 or Human Lymphocyte Protein or SECT or T Cell Serine Protease 1-3E or GZMB or EC 3.4.21.79) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Make an Enquiry: http://www.marketresearchhub.com/enquiry.php?type=enquiry&repid=1177485

About Market Research Hub:

Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Contact Details:

90 State Street,
Albany, NY 12207,
United States
Toll Free: 866-997-4948 (US-Canada)
Tel: +1-518-621-2074
Email: press@marketresearchhub.com
Website: http://www.marketresearchhub.com/
Read More Related News: https://www.industrynewsanalysis.com/

This release was published on openPR.